The appearance of troglitazone, a potent glucose-lowering agent, marked a significant chapter in the control of type 2 diabetes. However, its withdrawal from the market due to substantial hepatotoxicity spurred broad investigation into related thiazolidinediones. Subsequently pioglitazone and rosiglitazone emerged, offering analogous mechanisms of